Latest Commercialisation News

Page 19 of 239
Clover Corporation has delivered record FY26 revenue of $97.4 million and a 50% lift in attributable profit, while raising its fully franked final dividend to 1.25 cents per share. The result comes alongside a planned chair transition, with Ian Glasson set to replace retiring chair Rupert Harrington after the 2026 AGM.
Victor Sage
Victor Sage
23 Sept 2026
Papyrus Australia moved its banana-fibre technology into early commercialisation during FY26, signing an estimated $4.2 million TBS supply contract and delivering commercial-scale samples. But the company ended the year with $257,077 cash, negative equity and an auditor-flagged material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
22 Sept 2026
Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.
Ada Torres
Ada Torres
22 Sept 2026
Simble Solutions is extending its NanoSensor technology into terrestrial solar monitoring, using its existing SimbleSense and CarbonView platforms as a potential route to commercialisation. The opportunity remains at the benchmark-testing stage, with space-based solar identified as a longer-term possibility rather than an immediate product or revenue stream.
Victor Sage
Victor Sage
22 Sept 2026
Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.
Ada Torres
Ada Torres
22 Sept 2026
Zeotech Limited (ASX:ZEO) is moving Toondoon toward its first direct-shipping kaolin export after securing a potential A$200 million offtake agreement, while AusPozz™ and zeoteCH₄® produce encouraging trial results. The progress came alongside an A$8.15 million FY26 loss, negative operating cash flow and an acknowledgement that further funding may be required.
Victor Sage
Victor Sage
21 Sept 2026
ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.
Victor Sage
Victor Sage
21 Sept 2026
CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.
Victor Sage
Victor Sage
21 Sept 2026
Jade Gas will use targeted 2D and 3D seismic to test whether its established coal-measure gas system extends into deeper CBM, shale gas and tight sandstone horizons in Mongolia. The exploration could expand TTCBM’s longer-term potential, but the company says commercialising existing resources remains the immediate priority.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.
Ada Torres
Ada Torres
21 Sept 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.
Ada Torres
Ada Torres
21 Sept 2026
BluGlass has begun a three-to-five-month, A$286,000 feasibility collaboration with global photonics company Coherent to develop a novel gallium nitride device for scientific and medical applications. The agreement offers technical and commercial promise, but does not yet include a production commitment or confirmed product launch.
Victor Sage
Victor Sage
21 Sept 2026

Browse the archive

Full archive